Tests baricitinib for long-term safety in children with juvenile arthritis
Tests the drug baricitinib in children with juvenile idiopathic arthritis, aged 1 to 17.
Plain-language title generated from the registry record
Registry title: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Key facts
- Where
- Brescia, Chieti, Genova, Milan, Naples, Palermo, and Trieste, ItalySee the 8 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 18 years old?
Source: NCT03773965, who can take part
Where in Italy
- Azienda Ospedaliera Spedali Civili di BresciaBrescia, ItalyNo longer taking part
- Azienda Sanitaria Locale n. 2 - Lanciano Vasto ChietiChieti, ItalyNo longer taking part
- IRCCS Istituto Giannina GasliniGenova, ItalyNo longer taking part
- Centro Specialistico Ortopedico Traumatologico Gaetano Pini CTOMilan, ItalyNot yet recruiting
- Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilan, ItalyNo longer taking part
- University of Naples Federico IINaples, ItalyNo longer taking part
- Azienda di Rilievo Nazionale e Alta Specializzazione Civico Di Cristina BenfratelliPalermo, ItalyNot yet recruiting
- Ospedale Infantile Burlo GarofoloTrieste, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT03773965
- Record updated
- 4 November 2026
- Original description
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.Read full original descriptionShow less
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
Inclusion: Participants must have completed a previous study of baricitinib for the treatment of JIA.
Exclusion: Participants must not have had a permanent discontinuation of baricitinib in the prior study; Participants must have not developed an allergy to baricitinib.